TRCT
NEUP

Tower Research Capital (TRC)’s Neuphoria Therapeutics NEUP Stock Holding History

Tower Research Capital (TRC)’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,400
Closed -$5.43K – 5683
2025
Q4 		$5.43K Buy
1,400
+990
+241% +$7.03K ﹤0.01% 4124
2025
Q3 		$4.83K Buy
+410
New +$3.81K ﹤0.01% 4291
2024
Q1 		– Sell
-134
Closed -$2.38K – 6217
2023
Q4 		$2.38K Buy
134
+129
+2,580% +$3.68K ﹤0.01% 5225
2023
Q3 		$146 Buy
+5
New +$108 ﹤0.01% 5686
2022
Q1 		– Sell
-8
Closed -$1K – 6636
2021
Q4 		$1K Buy
+8
New +$1.23K ﹤0.01% 5903

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Tower Research Capital (TRC)'s NEUP Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Neuphoria Therapeutics (NEUP) in Q1 2026, closing a stake of 1,400 shares — an estimated $5.43K sold.

Tower Research Capital (TRC) first reported a position in NEUP in Q4 2021 and held it in 5 quarters. The position peaked at $5.43K in Q4 2025. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Neuphoria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,400 Neuphoria Therapeutics shares in Q1 2026, an estimated $5.43K.
  • Tower Research Capital (TRC) first reported a position in Neuphoria Therapeutics in Q4 2021 and held it in 5 quarters.
  • Tower Research Capital (TRC)'s Neuphoria Therapeutics position peaked at $5.43K in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.